Richard C. Hubbard

11.0k citations

81 papers · 8.6k indexed · 4 hit papers · h-index 48

Pulmonary and Respiratory Medicine top 0.5%
Pharmacology top 0.1%
Surgery top 2%
Physiology top 2%
Molecular Biology top 10%

Co-authors: Ronald G. Crystal André M. Cantin Gilbert Geis Susan L. North G A Fells Peter C. Isakson Tricia M. McKeever Andrew Fogarty
Topics: Inflammatory mediators and NSAID effects (29 papers)Anesthesia and Pain Management (14 papers)Protease and Inhibitor Mechanisms (11 papers)
Cited by: Pharmacology Biochemistry Anesthesiology and Pain Medicine
Journals: Science New England Journal of Medicine Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Germany

In The Last Decade

Richard C. Hubbard

77 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Normal alveolar epithelial lining fluid contains high levels of glutathione

1987 680 citations André M. Cantin, Richard C. Hubbard et al. profile →
Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis

1999 636 citations Lee S. Simon, Peter E. Lipsky et al. profile →
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review

2015 630 citations Richard C. Hubbard et al. profile →
Glutathione Deficiency in the Epithelial Lining Fluid of the Lower Respiratory Tract in Idiopathic Pulmonary Fibrosis

1989 383 citations André M. Cantin, Richard C. Hubbard et al. American Review of Respiratory Disease profile →

Peers

Countries citing papers authored by Richard C. Hubbard

Since Specialization

Citations

This map shows the geographic impact of Richard C. Hubbard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Hubbard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Hubbard more than expected).

Fields of papers citing papers by Richard C. Hubbard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Hubbard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Hubbard. The network helps show where Richard C. Hubbard may publish in the future.

Co-authorship network of co-authors of Richard C. Hubbard

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Hubbard. A scholar is included among the top collaborators of Richard C. Hubbard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Hubbard. Richard C. Hubbard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	What is the Definition of Cure in Non-small Cell Lung Cancer? 2021 ·Oncology and Therapy ·(unknown),Libby Ellis,Emma O’Dowd,Rachael L Murray,Richard C. Hubbard,David Baldwin	8
2	P2.16-21 Post-Treatment Survival Difference Between Lobectomy and Stereotactic Ablative Radiotherapy in Stage 1 Non-Small Cell Lung Cancer in England 2018 ·Journal of Thoracic Oncology ·Aamir Khakwani,Susan Harden,Neal Navani,Paul Beckett,Richard C. Hubbard	0
3	The Cyclooxygenase-2-Specific Inhibitor Parecoxib Sodium Is as Effective as 12 mg of Morphine Administered Intramuscularly for Treating Pain After Gynecologic Laparotomy Surgery 2005 ·Anesthesia & Analgesia ·T. Philip Malan,S. C. GORDON,Richard C. Hubbard,Michael C. Snabes	37
4	A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy 2004 ·American Journal of Obstetrics and Gynecology ·George B. Bikhazi,Michael C. Snabes,Zahid H. Bajwa,(unknown),D Lecomte,Louise Traylor,Richard C. Hubbard	38
5	Analgesic Efficacy of Preoperative Parecoxib Sodium in an Orthopedic Pain Model 2004 ·Journal of the American Podiatric Medical Association ·Paul J. Desjardins,Louise Traylor,Richard C. Hubbard	29
6	Parecoxib Sodium, a Parenteral Cyclooxygenase 2 Selective Inhibitor, Improves Morphine Analgesia and Is Opioid-sparing following Total Hip Arthroplasty 2003 ·Anesthesiology ·T. Philip Malan,(unknown),(unknown),(unknown),Louise Traylor,Richard C. Hubbard	125
7	Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia † 2003 ·British Journal of Anaesthesia ·Richard C. Hubbard,(unknown),(unknown),Shobha Dhadda	106
8	Intravenous parecoxib sodium foracute pain after orthopedic knee surgery. 2002 ·PubMed ·G. Lynn Rasmussen,Karen Steckner,Charles W. Hogue,Sarah Torri,Richard C. Hubbard	66
9	Reduced Incidence of Gastroduodenal Ulcers With Celecoxib, A Novel Cyclooxygenase-2 Inhibitor, Compared To Naproxen in Patients With Arthritis 2001 ·The American Journal of Gastroenterology ·Jay L. Goldstein,P Corréa,(unknown),Aimee Burr,Richard C. Hubbard,(unknown),Gilbert Geis	155
10	Increased Risk of Fibrosing Alveolitis Associated with Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor- α Gene Polymorphisms 2000 ·American Journal of Respiratory and Critical Care Medicine ·(unknown),Richard C. Hubbard,Riccardo Melicòni,(unknown),(unknown),Colin D. Bingle,J. M. Timms,Gordon W. Duff,(unknown),Angela Maria Grazia Pacilli,Mario Fabbri,Ian P. Hall,John Britton,Ian Johnston,F Giovine	141
11	Reduced Risk of Upper Gastrointestinal Ulcer Complications With Celecoxib, A Novel Cox-2 Inhibitor 2000 ·The American Journal of Gastroenterology ·Jay L. Goldstein,Fred E. Silverstein,Naurang M. Agrawal,Richard C. Hubbard,(unknown),Clement Maurath,Kenneth M. Verburg,(unknown)	232
12	Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison 1999 ·The Lancet ·Paul Emery,H. Zeidler,Tore K Kvien,Mario Guslandi,(unknown),Helen Stead,Kenneth M. Verburg,Peter C. Isakson,Richard C. Hubbard,Gilbert Geis	410
13	Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects 1998 ·Arthritis & Rheumatism ·Lee S. Simon,Frank L. Lanza,Peter E. Lipsky,Richard C. Hubbard,Sheela Talwalker,Benjamin D. Schwartz,Peter C. Isakson,Gilbert Geis	405
14	Conversion from Twice-to Once-Daily Extended-Release Theophylline Treatment in Patients with Reversible Airway Obstruction 1995 ·Journal of Asthma ·Robert Berkowitz,David G. Tinkelman,Judith Marcoux,Anthony R. Rooklin,H Zeitz,Stephen I. Rennard,(unknown),Richard C. Hubbard,Richard Lorber	2
15	Protease-Antiprotease Imbalance in the Lungs of Children with Cystic Fibrosis 1994 ·American Journal of Respiratory and Critical Care Medicine ·P. Birrer,Noel G. McElvaney,A Rüdeberg,(unknown),Sabina Liechti‐Gallati,Richard Kraemer,Richard C. Hubbard,Ronald G. Crystal	315
16	A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis 1992 ·New England Journal of Medicine ·Richard C. Hubbard,Noel G. McElvaney,P. Birrer,Steven Shak,(unknown),(unknown),Margaret Wu,Milica S. Chernick,Ronald G. Crystal	158
17	Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract. 1990 ·Journal of Clinical Investigation ·André M. Cantin,G A Fells,Richard C. Hubbard,Ronald G. Crystal	108
18	Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency 1988 ·The American Journal of Medicine ·Richard C. Hubbard,Ronald G. Crystal	53
19	Evaluation of the S-type of Alpha-1-Antitrypsin as an In Vivo and In Vitro Inhibitor of Neutrophil Elastase 1988 ·American Review of Respiratory Disease ·Fumitaka Ogushi,Richard C. Hubbard,G A Fells,Mario Casolaro,David T. Curiel,Mark Brantly,Ronald G. Crystal	48
20	Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. 1987 ·Journal of Clinical Investigation ·Fumitaka Ogushi,G A Fells,Richard C. Hubbard,(unknown),Ronald G. Crystal	161

About Richard C. Hubbard

Richard C. Hubbard is a scholar working on Pharmacology, Anesthesiology and Pain Medicine and Pulmonary and Respiratory Medicine, having authored 81 papers that have together received 8.6k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (29 papers), Anesthesia and Pain Management (14 papers) and Protease and Inhibitor Mechanisms (11 papers). The work is most often cited by research in Pharmacology (2.9k citations), Biochemistry (817 citations) and Anesthesiology and Pain Medicine (549 citations). Richard C. Hubbard has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ronald G. Crystal, André M. Cantin, Gilbert Geis, Susan L. North, G A Fells, Peter C. Isakson, Tricia M. McKeever, Andrew Fogarty, John W. Hutchinson and Kenneth M. Verburg. Their work appears in journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact